Contrary to this approach, and germane to the pathophysiology of a patient’s cancer, is whether cancer cells can synthesize ATRA from all-trans retinol for the activation of RARs, and whether there is constitutive disruption to ATRA-driven RAR-mediated events. The gene discussed is RARA; the disease is cancer.